Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2017

Open Access 01-12-2017 | Research article

Modelling the effects of booster dose vaccination schedules and recommendations for public health immunization programs: the case of Haemophilus influenzae serotype b

Authors: Nadia A. Charania, Seyed M. Moghadas

Published in: BMC Public Health | Issue 1/2017

Login to get access

Abstract

Background

Haemophilus influenzae serotype b (Hib) has yet to be eliminated despite the implementation of routine infant immunization programs. There is no consensus regarding the number of primary vaccine doses and an optimal schedule for the booster dose. We sought to evaluate the effect of a booster dose after receiving the primary series on the long-term disease incidence.

Methods

A stochastic model of Hib transmission dynamics was constructed to compare the long-term impact of a booster vaccination and different booster schedules after receiving the primary series on the incidence of carriage and symptomatic disease. We parameterized the model with available estimates for the efficacy of Hib conjugate vaccine and durations of both vaccine-induced and naturally acquired immunity.

Results

We found that administering a booster dose substantially reduced the population burden of Hib disease compared to the scenario of only receiving the primary series. Comparing the schedules, the incidence of carriage for a 2-year delay (on average) in booster vaccination was comparable or lower than that observed for the scenario of booster dose within 1 year after primary series. The temporal reduction of symptomatic disease was similar in the two booster schedules, suggesting no superiority of one schedule over the other in terms of reducing the incidence of symptomatic disease.

Conclusions

The findings underscore the importance of a booster vaccination for continued decline of Hib incidence. When the primary series provides a high level of protection temporarily, delaying the booster dose (still within the average duration of protection conferred by the primary series) may be beneficial to maintain longer-term protection levels and decelerate the decline of herd immunity in the population.
Appendix
Available only for authorised users
Literature
1.
2.
World Health Organization. Haemophilus influenzae type b (Hib) vaccination position paper – July 2013. Wkly Epidemiol Rec. 2013;88(39):413–26.
3.
Adams WG, Deaver KA, Cochi SL, Plikaytis BD, Zell ER, Broome CV, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA. 1993;269(2):221–6.CrossRefPubMed
4.
Galil K, Singleton R, Levine OS, Fitzgerald MA, Bulkow L, Getty M, et al. Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska. J Infect Dis. 1999;179(1):101–6.CrossRefPubMed
5.
Oh SY, Griffiths D, John T, Lee YC, Yu LM, McCarthy, et al. School-aged children: a reservoir for continued circulation of Hib in the United Kingdom. J Infect Dis. 2008;197(9):1275–81.CrossRefPubMed
6.
Jackson ML, Rose CE, Cohn A, Coronado F, Clark TA, Wenger JD, et al. Modeling insights into Haemophilus influenzae type b disease, transmission, and vaccine programs. Emerg Infec Dis. 2012;18(1):13–20.CrossRef
7.
Halperin SA, King J, Law B, Mills E, Willems P. Safety and immunogenicity of Haemophilus influenzae - tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses. Clin Infect Dis. 1999;28(5):995–1001.CrossRefPubMed
8.
McVernon J, Andrews N, Slack MP, Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet. 2003;361(9368):1521–3.CrossRefPubMed
9.
Johnson NG, Ruggeberg JU, Balfour GF, Lee YC, Liddy H, Irving D, et al. Haemophilus influenzae type b reemergence after combination immunization. Emerg Infect Dis. 2006;12(6):937–41.CrossRefPubMedPubMedCentral
10.
Ladhani S, Slack MP, Heys M, White J, Ramsay ME. Fall in Haemophilus influenzae serotype b (Hib) disease following implementation of a booster campaign. Arch Dis Child. 2008;93(8):665–9.CrossRefPubMed
11.
Morris SK, Moss WJ, Halsey N. Haemophilus influenzae type b conjugate vaccine use and effectiveness. Lancet Infect Dis. 2008;8(7):435–43.CrossRefPubMed
12.
Trotter CL, McVernon J, Ramsay ME, Whitney CG, Mulholland EK, Goldblatt D, Hombach J, Kieny MP. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine. 2008;26(35):4434–45.CrossRefPubMed
13.
Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis. 2003;188(4):481–5.CrossRefPubMed
14.
Trotter CL, Ramsay ME, Slack MP. Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign. Commun Dis Public Health. 2003;6(1):55–8.PubMed
15.
Omer SB, Salmon DA, Orenstein WA, deHart P, Halsey N. Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases. N Engl J Med. 2009;360(19):1981–8.CrossRefPubMed
16.
17.
Briere EC, Jackson M, Shah SG, Cohn AC, Anderson RD, MacNeil JR, et al. Haemophilus influenzae type b disease and vaccine booster dose deferral, United States, 1998-2009. Pediatrics. 2012;130(3):414–20.CrossRefPubMedPubMedCentral
18.
19.
Fitzwater SP, Watt JP, Levine OS, Santosham M. Haemophilus influenzae type b conjugate vaccines: considerations for vaccination schedules and implications for developing countries. Hum Vaccine. 2010;6(10):810–8.CrossRef
20.
Centers for Disease Control and Prevention. Haemophilus influenzae. In: Hamborsky J, Kroger A, Wolfe S, editors. Epidemiology and prevention of vaccine-preventable diseases. 13th edition. Public Health Foundation, Washington D.C.; 2012.
21.
Obonyo CO, Lau J. Efficacy of Haemophilus influenzae type b vaccination of children: a meta-analysis. Eur J Clin Microbiol Infect Dis. 2006;25(2):90–7.CrossRefPubMed
22.
Jackson C, Mann A, Mangtani P, Fine P. Effectiveness of Haemophilus influenzae type b vaccines administered according to various schedules: systematic review and meta-analysis of observational data. Pediatr Infect Dis J. 2013;32(11):1261–9.CrossRefPubMed
23.
Anderson RM, May RM. Infectious diseases of humans: dynamics and control. Oxford: Oxford University Press; 1992.
24.
Xiao Y, Brauer F, Moghadas SM. Can treatment increase the epidemic size? J Math Biol. 2016;72(1–2):343–61.CrossRefPubMed
25.
Gillespie DT. Exact stochastic simulation of coupled chemical reactions. J Phys Chem. 1977;81(25):2340–61.CrossRef
26.
Farrington CP, Kanaan MN, Gay NJ. Estimation of the basic reproduction number for infectious diseases from age-stratified serological survey data. Appl Stat. 2001;50(3):251–92.
27.
Auranen K, Eichner M, Leino T, Takala AK, Mäkelä PH, Takala T. Modelling transmission, immunity and disease of Haemophilus influenzae type b in a structured population. Epidemiol Infect. 2004;132(05):947–57.CrossRefPubMedPubMedCentral
28.
Coen PG, Heath PT, Garnett GP. The Hib immunization programme in the Oxford region: an analysis of the impact of vaccine administration on the incidence of disease. Epidemiol Infect. 1999;123(3):389–402.CrossRefPubMedPubMedCentral
29.
30.
Konini A, Moghadas SM. Modelling the impact of vaccination on curtailing Haemophilus influenzae serotype ‘a’. J Theor Biol. 2015;387:101–10.CrossRefPubMed
31.
Konini A, Nix E, Ulanova M, Moghadas SM. Dynamics of naturally acquired antibody against Haemophilus influenzae type a capsular polysaccharide in a Canadian aboriginal population. Prev Med Rep. 2016;3:145–50.CrossRefPubMedPubMedCentral
32.
Leino T, Auranen K, Mäkelä PH, Käyhty H, Takala AK. Dynamics of natural immunity caused by subclinical infections, case study on Haemophilus influenzae type b (Hib). Epidemiol Infect. 2000;125(3):583–91.CrossRefPubMedPubMedCentral
33.
Heymann DL. Hemophilus meningitis. In: Control of Communicable Diseases Manual. 18th ed. Washington: American Public Health Association; 2004.
34.
Heath PT, Booy R, Azzopardi HJ, Slack MPE, Bowen-Morris J, Griffiths H, et al. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA. 2000;284(18):2334–40.CrossRefPubMed
35.
Rodriguez RS, Mascarenas C, Conde-Glez CJ, Inostroza J, Villanueva S, Velázquez ME, Sánchez-Alemán MA, Echániz G. Serological protection induced by Haemophilus influenzae type B conjugate vaccine in Mexican children: is a booster dose of the vaccine needed? Clin Vaccine Immunol. 2010;17(10):1639–41.CrossRefPubMedPubMedCentral
36.
Hammitt LL, Crane RJ, Karani A, Mutuku A, Morpeth SC, Burbidge P, Goldblatt D, Kamau T, Sharif S, Mturi N, Scott JA. Effect of Haemophilus influenzae type b vaccination without a booster dose on invasive H influenzae type b disease, nasopharyngeal carriage, and population immunity in Kilifi, Kenya: a 15-year regional surveillance study. Lancet Glob Health. 2016;4(3):e185–94.CrossRefPubMedPubMedCentral
37.
Howie SR, Oluwalana C, Secka O, Scott S, Ideh RC, Ebruke BE, Balloch A, Sambou S, Erskine J, Lowe Y, Corrah T, Adegbola RA. The effectiveness of conjugate Haemophilus influenzae type B vaccine in the Gambia 14 years after introduction. Clin Infect Dis. 2013;57(11):1527–34.CrossRefPubMedPubMedCentral
38.
Southern J, McVernon J, Gelb D, Andrews N, Morris R, Crowley-Luke A, Goldblatt D, Miller E. Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in infancy. Clin Vaccine Immunol. 2007;14(10):1328–33.CrossRefPubMedPubMedCentral
39.
Ladhani S, Ramsay M, Flood J, Campbell H, Slack M, Pebody R, et al. Haemophilus influenzae serotype b (Hib) seroprevalence in England and Wales in 2009. Euro Surveill. 2012;17(46):pii-20313.
40.
Ulanova M, Tsang RSW. Haemophilus influenzae serotype a as a cause of serious invasive infections. Lancet Infect Dis. 2014;14(1):70–82.CrossRefPubMed
41.
McVernon J, Ramsay ME, McLean AR. Understanding the impact of Hib conjugate vaccine on transmission, immunity and disease in the United Kingdom. Epidemiol Infect. 2008;136(6):800–12.CrossRefPubMed
42.
Lagergård T, Branefors P. Nature of cross-reactivity between Haemophilus influenzae types a and b and Streptococcus pneumoniae types 6A and 6B. Acta Path Micro Im C. 1983;91(6):371–6.
43.
Fekete A, Hoogerhout P, Zomer G, Kubler-Kielb J, Schneerson R, Robbins JB, Pozsgay V. Synthesis of octa-and dodecamers of D-ribitol-1-phosphate and their protein conjugates. Carbohydr Res. 2006;341(12):2037–48.CrossRefPubMed
44.
Leino T, Auranen K, Makela PH, Kayhty H, Takala AK. Haemophilus influenzae type b and cross-reactive antigens in natural Hib infection dynamics: modelling in two populations. Epidemiol Infect. 2002;129(1):73–83.CrossRefPubMedPubMedCentral
Metadata
Title
Modelling the effects of booster dose vaccination schedules and recommendations for public health immunization programs: the case of Haemophilus influenzae serotype b
Authors
Nadia A. Charania
Seyed M. Moghadas
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2017
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-017-4714-9

Other articles of this Issue 1/2017

BMC Public Health 1/2017 Go to the issue

Research article

A household survey of medicine storage practices in Gondar town, northwestern Ethiopia

Research article

Metabolic syndrome and its components among university students in Kenya

Study protocol

Community-based randomized controlled trial of diabetes prevention study for high-risk individuals of type 2 diabetes: lifestyle intervention using web-based system

Research article

Health literacy in childhood and youth: a systematic review of definitions and models

Research article

The prevalence of the metabolic syndrome in a farm worker community in the Boland district, South Africa

Research article

Health risk assessment of China’s main air pollutants